Arax Advisory Partners Sells 24,815 Shares of Boston Scientific Corporation $BSX

Arax Advisory Partners trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 64.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 13,662 shares of the medical equipment provider’s stock after selling 24,815 shares during the quarter. Arax Advisory Partners’ holdings in Boston Scientific were worth $1,303,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. FWL Investment Management LLC bought a new stake in Boston Scientific in the second quarter valued at $26,000. Swiss RE Ltd. bought a new stake in Boston Scientific in the fourth quarter valued at $26,000. Colonial Trust Co SC grew its position in Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 231 shares during the period. Bangor Savings Bank grew its position in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the period. Finally, Board of the Pension Protection Fund bought a new stake in Boston Scientific in the fourth quarter valued at $29,000. 89.07% of the stock is currently owned by institutional investors.

Insider Activity at Boston Scientific

In other news, Director David C. Habiger bought 2,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director owned 13,878 shares in the company, valued at $776,057.76. This represents a 19.35% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Cheryl Pegus bought 1,770 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

BSX has been the topic of several research analyst reports. Zacks Research cut Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Truist Financial decreased their target price on Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday, June 4th. Raymond James Financial restated an “outperform” rating and set a $88.00 target price (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Oppenheimer set a $90.00 target price on Boston Scientific in a report on Thursday, April 23rd. Finally, Piper Sandler restated an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $85.08.

Boston Scientific Trading Down 0.5%

Shares of BSX opened at $46.69 on Tuesday. Boston Scientific Corporation has a 12-month low of $45.99 and a 12-month high of $109.50. The stock’s fifty day simple moving average is $56.05 and its 200-day simple moving average is $74.40. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $69.39 billion, a PE ratio of 19.53, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to analyst estimates of $5.19 billion. During the same quarter in the prior year, the firm posted $0.75 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific announced that its board has initiated a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.